110
Participants
Start Date
July 31, 2004
Primary Completion Date
March 31, 2011
Study Completion Date
July 31, 2013
LEXIVA (GW433908)
Fosamprenavir suspension or tablet bid
Ritonavir
Ritonavir solution bid
GSK Investigational Site, Soweto
GSK Investigational Site, Antwerp
GSK Investigational Site, Coronationville
GSK Investigational Site, Durban
GSK Investigational Site, Parow Valley
GSK Investigational Site, New York
GSK Investigational Site, New York
GSK Investigational Site, New York
GSK Investigational Site, The Bronx
GSK Investigational Site, New Hyde Park
GSK Investigational Site, Philadelphia
GSK Investigational Site, Durham
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Málaga
GSK Investigational Site, Jacksonville
GSK Investigational Site, Tampa
GSK Investigational Site, Birmingham
GSK Investigational Site, Vigo ( Pontevedra)
GSK Investigational Site, Seville
GSK Investigational Site, Valencia
GSK Investigational Site, Dallas
GSK Investigational Site, Fort Worth
GSK Investigational Site, Los Angeles
GSK Investigational Site, Oakland
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Boston
GSK Investigational Site, Boston
GSK Investigational Site, Vancouver
GSK Investigational Site, Winnipeg
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Bucharest
GSK Investigational Site, Bucharest
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Palma de Mallorca
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY